Genfit S.A. GNFT Stock
Genfit S.A. Price Chart
Genfit S.A. GNFT Financial and Trading Overview
| Genfit S.A. stock price | 3.58 USD |
| Previous Close | 4.63 USD |
| Open | 4.61 USD |
| Bid | 0 USD x 2900 |
| Ask | 0 USD x 1100 |
| Day's Range | 4.54 - 4.65 USD |
| 52 Week Range | 3.11 - 5.05 USD |
| Volume | 27.6K USD |
| Avg. Volume | 8.55K USD |
| Market Cap | 242.63M USD |
| Beta (5Y Monthly) | 0.91839 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.62 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GNFT Valuation Measures
| Enterprise Value | 163.82M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 9.244581 |
| Price/Book (mrq) | 2.4447951 |
| Enterprise Value/Revenue | 6.242 |
| Enterprise Value/EBITDA | -6.329 |
Trading Information
Genfit S.A. Stock Price History
| Beta (5Y Monthly) | 0.91839 |
| 52-Week Change | 41.33% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.05 USD |
| 52 Week Low | 3.11 USD |
| 50-Day Moving Average | 4.1 USD |
| 200-Day Moving Average | 4.09 USD |
GNFT Share Statistics
| Avg. Volume (3 month) | 8.55K USD |
| Avg. Daily Volume (10-Days) | 17.11K USD |
| Shares Outstanding | 49.84M |
| Float | 41.09M |
| Short Ratio | 14.21 |
| % Held by Insiders | 0% |
| % Held by Institutions | 4.33% |
| Shares Short | 101.27K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -90.37% |
| Operating Margin (ttm) | -105.29% |
| Gross Margin | 100.00% |
| EBITDA Margin | -98.62% |
Management Effectiveness
| Return on Assets (ttm) | -6.94% |
| Return on Equity (ttm) | -22.20% |
Income Statement
| Revenue (ttm) | 26.25M USD |
| Revenue Per Share (ttm) | 0.53 USD |
| Quarterly Revenue Growth (yoy) | -82.79% |
| Gross Profit (ttm) | 26.25M USD |
| EBITDA | -25884000 USD |
| Net Income Avi to Common (ttm) | -23719000 USD |
| Diluted EPS (ttm) | -0.51 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 140.55M USD |
| Total Cash Per Share (mrq) | 2.83 USD |
| Total Debt (mrq) | 75.28M USD |
| Total Debt/Equity (mrq) | 79.63 USD |
| Current Ratio (mrq) | 4.025 |
| Book Value Per Share (mrq) | 1.902 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -72638000 USD |
| Levered Free Cash Flow (ttm) | -52878376 USD |
Profile of Genfit S.A.
| Country | United States |
| State | N/A |
| City | Loos |
| Address | Parc EurasantE |
| ZIP | 59120 |
| Phone | 33 3 20 16 40 00 |
| Website | https://www.genfit.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 148 |
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Q&A For Genfit S.A. Stock
What is a current GNFT stock price?
Genfit S.A. GNFT stock price today per share is 3.58 USD.
How to purchase Genfit S.A. stock?
You can buy GNFT shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genfit S.A.?
The stock symbol or ticker of Genfit S.A. is GNFT.
Which industry does the Genfit S.A. company belong to?
The Genfit S.A. industry is Biotechnology.
How many shares does Genfit S.A. have in circulation?
The max supply of Genfit S.A. shares is 50.11M.
What is Genfit S.A. Price to Earnings Ratio (PE Ratio)?
Genfit S.A. PE Ratio is now.
What was Genfit S.A. earnings per share over the trailing 12 months (TTM)?
Genfit S.A. EPS is -0.62 USD over the trailing 12 months.
Which sector does the Genfit S.A. company belong to?
The Genfit S.A. sector is Healthcare.
Genfit S.A. GNFT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}